valirx
Another small cap company that did well today was ValiRx (LON:VAL), whose shares soared 25.5 per cent at 0.87 pence in afternoon trade.
The buying spree came after ValiRx announced that a study conducted in collaboration with Oxford University found that one of its lead therapeutics might be effective in treating a type of prostate cancer.
According to the firm, the preclinical study has firmly established a potentially important role for the drug, VAL201, in treating hormone-induced refractory prostate cancer.
http://www.proactiveinvestors.co.uk...-royal-dutch-shell-sarantel-valirx-31267.html
----------------------------------------------------------------------
Valirx directors buy 2.8 mln shares at 0.63p2011-07-14 by Jamie Ashcroft
AIM-listed biotech firm Valirx (LON:VAL) told investors that four of its directors have been buying shares in the company.
In total the directors bought 2.8 million shares at 0.63 pence each.
In the most significant transaction chief executive Dr Satu Vainikka bought 1.23 million shares, taking her total holding to 17.8 million shares which equates to 1.71 percent of the company.
Gerry Desler, Valirx chief financial officer, bought 538,770 shares and he now holds 6.63 million shares, representing 0.64 percent of the company.
Non-executive directors George Morris and Kevin Alexander also bought 538,770 shares each. Morris now has 11.9 million shares, 1.14 percent of the company, and Alexander has 3.97 million shares representing 0.38 percent.
Valirx is developing a drug platform to silence rebellious genes that cause cancer and other diseases, while creating a potentially revenue-generating testing business.
The company made quite a splash earlier this year as its share price ran right the way up to 1.8 pence from 0.25 pence - a rise of over 600 per cent. On the back of this, the company was able to carry out a placing at 0.6 pence a share, raising £3.3 million.
This should see its two key potential cancer treatments - VAL101 and VAL201 - through the pre-clinical phase of development and into human trials.
VAL101 is based on the something called GeneICE, which is a tool for silencing rebellious genes. In that respect it is similar to the cutting siRNA technologies being used to target cancers. However according to Valirx GeneICE has the potential to be more specific, longer-acting and carries with it fewer side-effects.
Meanwhile VAL201 has being developed to target refractory prostate cancer, where there is huge unmet medical need.
http://www.proactiveinvestors.com.h...rx-directors-buy-2-8-mln-shares-at-0-63p.html
http://www.youtube.com/watch?v=KljYkLZGd9E